H2O America vs Liquidia Corporation Common Stock — how do they compare? H2O America trades at $57.11 (market cap $2.45B), while Liquidia Corporation Common Stock trades at $33.78 (market cap $2.40B). The key difference: H2O America and Liquidia Corporation Common Stock are close in size by market cap, and H2O America pays a 3.01% dividend while Liquidia Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold H2O America for 39 Days and Liquidia Corporation Common Stock for 0 Days on average.
| HTO | LQDA | |
|---|---|---|
Market Cap | $2.45B | $2.40B |
Volume | 419,336 | 2,857,547 |
Sector | Utilities | Health |
52-Week High | $65.43 | $91.03 |
52-Week Low | $44.44 | $22.02 |
Typical Hold Time | 39 Days | 0 Days |
Enterprise Value | $4.24B | $2.30B |
Dividend Yield | 3.01% | — |
Signals from Pluang's Aura AI — not financial advice
HTO trades at $58.49, down 0.27% with a bearish technical signal despite strong analyst support. The company shows solid fundamentals with 12.91% net income margin and consistent earnings beats in recent quarters. Recent acquisitions in Texas expand operations but require significant capital investment. Cash flow trends improved from $10M in 2025 to $84M in 2026, supporting dividend sustainability.
Outlook remains positive with 83% analyst buy ratings and $66.50 consensus target offering 14% upside. Key risks include acquisition integration and execution challenges. The stock presents value for income investors given Dividend King status and strategic growth initiatives in regulated water utilities.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →